Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06433999 · ClinicalTrials.gov registry record · Phase 2
A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
A Phase 2 study, sponsored by Priovant Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT06433999 is a Phase 2 study that has completed, run by Priovant Therapeutics. The registered enrollment target is 5 participants.
The verdict
NCT06433999, a Phase 2 study, has completed, sponsored by Priovant Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a prospective, 12-week, open-label, single-arm study. The study population comprises individuals with refractory skin disease characteristic of dermatomyositis with no to minimal muscle involvement. After an up to 8-week Screening Period, eligible participants will receive brepocitinib 30 mg orally (PO) QD for 12 weeks.
Interventions
- DRUG Brepocitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2025-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06433999
The ClinicalTrials.gov registry entry for NCT06433999 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Priovant Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brepocitinib is the first listed.
NCT06433999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06433999 about?
NCT06433999 is a clinical study titled "A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis". This is a prospective, 12-week, open-label, single-arm study. The study population comprises individuals with refractory skin disease characteristic of dermatomyositis with no to minimal muscle involvement. After an up to 8-week Screening Period, eligible participants will receive brepocitinib 30 mg...
What is the current status of trial NCT06433999?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2024-08-28. Estimated completion is 2025-02-28.
What interventions are being tested in trial NCT06433999?
The interventions under investigation include: Brepocitinib (DRUG).
Who is sponsoring clinical trial NCT06433999?
This trial is sponsored by Priovant Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.